PSA efficacy and pharmacodynamic analysis
The median baseline PSA for the placebo and metformin cohort was 31.95 (5.7–77.15) and 25 (6.2–58.7) respectively (Phospho-S6-kinase levels were analyzed from patient derived blood samples and although there were some downregulation in patients 7, 25, 34 and 37 who received metformin, overall variable regulation of protein levels on western blot in both metformin and placebo cohorts at all time points measured (